Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2022.1185
Abstract: Key Points Question What is the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis? Findings In this cohort study including 1789 patients receiving bimekizumab, pooled data on 2 years of… read more here.
Keywords: safety; patients moderate; moderate severe; plaque psoriasis ... See more keywords
Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Dermatological Research"
DOI: 10.1007/s00403-019-02024-6
Abstract: Etanercept biosimilar recombinant human tumour necrosis factor-α receptor II: IgG Fc fusion protein (rhTNFR-Fc, trade name Yisaipu) has shown good efficacy in the treatment of moderate-to-severe plaque psoriasis. To compare the efficacy and safety of… read more here.
Keywords: severe plaque; plaque psoriasis; moderate severe; rhtnfr plus ... See more keywords
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-01049-7
Abstract: Psoriasis is an immune-mediated, chronic, inflammatory disease, which has a substantial humanistic and economic burden. This study aimed to assess the impact of this disease on health-related quality of life (HRQoL), work productivity, and direct… read more here.
Keywords: humanistic economic; severe plaque; psoriasis; plaque psoriasis ... See more keywords
Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
Sign Up to like & getrecommendations! Published in 2019 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2019.05.042
Abstract: Etanercept has greatly improved management considerably. However, the efficacy and safety of combination therapy with methotrexate and the mechanism of action are not known. We aimed to describe the use of combined therapy of etanercept… read more here.
Keywords: combination; severe plaque; group; plaque psoriasis ... See more keywords
Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2020.1747592
Abstract: Abstract Background It is challenging to select the most appropriate biologic treatment for patients with moderate-to-severe plaque psoriasis. Objective To compare speed of onset and level of skin improvement between the interleukin (IL)-17A antagonist ixekizumab… read more here.
Keywords: p19; moderate severe; psoriasis; severe plaque ... See more keywords
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2020.1757017
Abstract: Abstract Background Cyclosporine A (CsA) is one of the systemic therapeutic options for moderate-to-severe psoriasis, based on its efficacy and rapidity of action. The current study investigated the response to CsA in patients with moderate-to-severe… read more here.
Keywords: study; plaque psoriasis; moderate severe; psoriasis ... See more keywords
Investigational systemic drugs for moderate to severe plaque psoriasis: What’s new?
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2023.2184684
Abstract: ABSTRACT Introduction The therapeutic armamentarium for the treatment of psoriasis, a chronic inflammatory skin disease, is now reasonably broad and structured, with several therapeutic agents that demonstrated a successful long-term control of this condition. However,… read more here.
Keywords: investigational systemic; drugs moderate; systemic drugs; moderate severe ... See more keywords
Pharmacological management of severe plaque psoriasis in patients with cardiovascular disease.
Sign Up to like & getrecommendations! Published in 2022 at "Expert opinion on pharmacotherapy"
DOI: 10.1080/14656566.2022.2060739
Abstract: INTRODUCTION There is compelling evidence about the independent association between psoriasis and an increased risk of cardiovascular diseases, in particular myocardial infarction, chronic heart failure and cardiac arrythmia. This is due to both the higher… read more here.
Keywords: management severe; pharmacological management; plaque psoriasis; psoriasis patients ... See more keywords
Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000014042
Abstract: Background: Secukinumab has been approved for the treatment of moderate to severe plaque psoriasis. However, safety measures concerning drug administration is vital during treatment. Understanding the right way to administer drugs is important to reduce… read more here.
Keywords: severe plaque; treatment; drug; treatment moderate ... See more keywords
Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20602
Abstract: Current psoriasis therapies have little-to-no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE-4) inhibitor, is approved for moderate-to-severe psoriasis and considered a safe treatment option, that… read more here.
Keywords: complete clearance; psoriasis; severe plaque; roflumilast therapy ... See more keywords
Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study *
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20827
Abstract: Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)‐17A and IL‐17F, which is currently under investigation for treatment of moderate‐to‐severe plaque psoriasis. Maintenance dosing every 4 weeks is well established with IL‐17 inhibitors for… read more here.
Keywords: severe plaque; plaque psoriasis; treatment moderate; moderate severe ... See more keywords